Rezulin®

FDA asked the manufacturer of Rezulin® (troglitazone) - a drug used to treat type 2 diabetes mellitus - to remove the product from the market. The drug's manufacturer, Parke-Davis/Warner-Lambert, agreed to FDA's request.

Severe liver toxicity has been known to occur with Rezulin® since 1997. In consultation with FDA, Parke-Davis has strengthened the drug's labeling several times and has recommended close monitoring of liver function in patients taking Rezulin®.

In March 1999, FDA's Endocrine and Metabolic Drugs Advisory Committee reviewed the status of Rezulin® and its risk of liver toxicity and recommended continued availability of this drug in a select group of patients - patients not well controlled on other diabetes drugs.

Since then, FDA has continued to actively monitor adverse events associated with Rezulin®, as well as Avandia and Actos. After up to nine months of marketing experience with these two newer drugs, it has now become clear that these newer drugs have less risk of severe liver toxicity than Rezulin®.

Source: fda.gov

If you or a loved one has been harmed by Rezulin®, you may want to contact a Rezulin® attorney for more information.